ZVSA (ZyVersa) Multiplikator nilai perusahaan marang pendapatan

A strategic alliance with research centers strengthens the credit potential of ZyVersa Therapeutics (ZVSA). The EV/Sales multiple trajectory on the GURU.Markets chart demonstrates stability, where the mark reflects the latest data. Financial stability is based on nephropathy and chronic inflammation therapies, while operational reliability is guaranteed by a diversified raw material supply system and established inventory reserves.
ZVSA (ZyVersa Therapeutics Inc.): rincian analitis lan laporan miturut indikator

This indicator determines the enterprise value of the business, accounting for net debt, and compares it to the volume of generated sales to identify asset overvaluation. By analyzing the EV/Revenue ratio, an investor assesses the efficiency of the ZyVersa Therapeutics (ZVSA) model, where the absence of proprietary manufacturing plants and a reliance on outsourcing make this coefficient a key measure of intellectual property value relative to operating revenues.